BACKGROUND: Aminosalicylates (5-ASA) are first-line treatment for mild-moderate ulcerative colitis (UC). Systemic corticosteroids (CS) are considered for patients in whom 5-ASA has been unsuccessful, but their use is limited by adverse effects. Beclomethasone dipropionate (BDP), a topically acting steroid with low systemic bioavailability, has a more favorable safety profile, but its role in clinical practice is not yet well established. AIM: The aim of the present study is to assess whether oral BDP can be an alternative treatment to systemic CS for patients with mild-moderate UC not responding to first-line therapy with 5-ASA. METHODS: From 2003 to 2006, all consecutive patients with mild-moderate UC unresponsive to oral and topical 5-ASA (+/-topical CS) administered for at least 3 weeks received an 8-week course of oral BDP (10 mg/day for 4 weeks and 5 mg/day for an additional 4 weeks). Co-primary end-points were: (1) clinical remission within 8 weeks, without need of systemic CS; (2) steroid-free remission for 12 months. RESULTS: Sixty-four patients were included. In this study, within 8 weeks, 48/64 patients (75%) entered remission without systemic CS, while 16/64 (25%) failed to enter remission. Within 12 months, 37/64 patients (58%) had prolonged steroid-free remission, while 11/64 (17%) relapsed. During 1 year, 75% of patients receiving oral BDP could avoid systemic CS. CONCLUSIONS: Oral BDP can avoid the use of systemic CS in the vast majority of patients with mild-moderate UC not responding to 5-ASA and could be considered as a second-line treatment for these patients.
BACKGROUND:Aminosalicylates (5-ASA) are first-line treatment for mild-moderate ulcerative colitis (UC). Systemic corticosteroids (CS) are considered for patients in whom 5-ASA has been unsuccessful, but their use is limited by adverse effects. Beclomethasone dipropionate (BDP), a topically acting steroid with low systemic bioavailability, has a more favorable safety profile, but its role in clinical practice is not yet well established. AIM: The aim of the present study is to assess whether oral BDP can be an alternative treatment to systemic CS for patients with mild-moderate UC not responding to first-line therapy with 5-ASA. METHODS: From 2003 to 2006, all consecutive patients with mild-moderate UC unresponsive to oral and topical 5-ASA (+/-topical CS) administered for at least 3 weeks received an 8-week course of oral BDP (10 mg/day for 4 weeks and 5 mg/day for an additional 4 weeks). Co-primary end-points were: (1) clinical remission within 8 weeks, without need of systemic CS; (2) steroid-free remission for 12 months. RESULTS: Sixty-four patients were included. In this study, within 8 weeks, 48/64 patients (75%) entered remission without systemic CS, while 16/64 (25%) failed to enter remission. Within 12 months, 37/64 patients (58%) had prolonged steroid-free remission, while 11/64 (17%) relapsed. During 1 year, 75% of patients receiving oral BDP could avoid systemic CS. CONCLUSIONS: Oral BDP can avoid the use of systemic CS in the vast majority of patients with mild-moderate UC not responding to 5-ASA and could be considered as a second-line treatment for these patients.
Authors: F Rizzello; P Gionchetti; R Galeazzi; G Novelli; D Valpiani; A D'Arienzo; F Manguso; G Castiglione; G Varoli; M Campieri Journal: Adv Ther Date: 2001 Nov-Dec Impact factor: 3.845
Authors: P Marteau; C S Probert; S Lindgren; M Gassul; T G Tan; A Dignass; R Befrits; G Midhagen; J Rademaker; M Foldager Journal: Gut Date: 2005-07 Impact factor: 23.059
Authors: F Rizzello; P Gionchetti; A D'Arienzo; F Manguso; G Di Matteo; V Annese; D Valpiani; T Casetti; S Adamo; A Prada; G N Castiglione; G Varoli; M Campieri Journal: Aliment Pharmacol Ther Date: 2002-06 Impact factor: 8.171
Authors: M Campieri; S Adamo; D Valpiani; A D'Arienzo; G D'Albasio; M Pitzalis; P Cesari; T Casetti; G N Castiglione; F Rizzello; F Manguso; G Varoli; P Gionchetti Journal: Aliment Pharmacol Ther Date: 2003-06-15 Impact factor: 8.171
Authors: Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez Journal: World J Hepatol Date: 2015-03-27
Authors: Thomas De Corte; Emilie Janssens; Ann D'Hondt; Koen Thorrez; Joris Arts; Katrien Dejaegher; François D'Heygere; Annelies Holvoet; Bart van Besien; Luc Harlet; Harald Peeters; Wouter Van Moerkercke; Filip Baert Journal: United European Gastroenterol J Date: 2019-07-12 Impact factor: 4.623
Authors: María Galvez-Llompart; María Del Carmen Recio Iglesias; Jorge Gálvez; Ramón García-Domenech Journal: Mol Divers Date: 2013-06-23 Impact factor: 2.943
Authors: Francesco Manguso; Raffaele Bennato; Giovanni Lombardi; Elisabetta Riccio; Giuseppe Costantino; Walter Fries Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240
Authors: Chang Hwan Choi; Won Moon; You Sun Kim; Eun Soo Kim; Bo-In Lee; Yunho Jung; Yong Sik Yoon; Heeyoung Lee; Dong Il Park; Dong Soo Han Journal: Intest Res Date: 2017-01-31